We offer cell line development capabilities from our facility in Morgan Hill, United States while MaB process development and manufacturing capabilities from our Bengaluru, Indian facility. Since Fiscal 2019, we have developed and delivered 54 cell lines to customers.
In addition, more than four of our cell lines are currently used in marketed products as of March 31, 2026. Our researchers have experience across multiple host cell lines including CHO-DG44, CHO-GS, SP2/0 and NS0, and expression systems such as DHFR and glutamine synthetase (GS). We also offer the royalty-free “CHOMax” platform which supports CHO-DG44 and CHO-GS cell lines, enabling accelerated cell line engineering and improved titers.
We offer specialized process development and technology transfer capabilities for biosimilars and continue to expand our capabilities in complex biologics. Our platform is further being strengthened through investments in new modalities including ADCs as well as integrated DS-DP capabilities.
Experience in executing parallel processing and focused analytics to mitigate risks to client programs and shorten the timeline to IND, with scalable and reproducible processes.
